BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Policy

  Pfizer and Flynn Under Fire Again for Alleged Overpricing of Anti-Epilepsy Drug

  Pfizer and Flynn Pharma are under the scrutiny of British watchdogs once again, after officials said the companies have been overcharging for an anti-epilepsy medication in the U.K. for over four years.

  July 22, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano M.S.
• 

  Drug Development

  Scientific Community Questions Anti-Amyloid Theory - the Basis for Seminal Alzheimer’s Work

  The data used to support the argument that Aβ*56 is responsible for the Alzheimer’s Disease hallmark of memory loss appears to have been fabricated or heavily tampered with.

  July 22, 2022

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Job Trends

  Astellas to Advance Cell, Gene Therapy with New $70M Bay Area Facility

  Astellas is investing around $70 million, providing lab and co-working spaces to support current and future growth initiatives in the cell and gene therapy space for cancer and rare diseases.

  July 22, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Clinical Catch-Up: Prometheus, Algernon, Seelos, Inozyme and Takeda

  Prometheus completed its Phase II trial in UC, Algernon announced its Phase II trial of IPF and chronic coffee, Seelos dosed the first patient of SLS-005 for patients with ALS.

  July 22, 2022

   · 

  5 min read

   · 

  Mark Terry
• 

  Drug Development

  mRNA’s Next Act: Cancer Vaccines and Gene Editing

  “The applications for mRNA are quite broad, because, basically, you are giving information to a cell to make any protein you want,” CureVac CFO Pierre Kemula told BioSpace.

  July 22, 2022

   · 

  4 min read

   · 

  Gail Dutton
• 

  FDA

  FDA Weekly Review: Avadel, Eton, Pfizer, Celcuity and Others

  FDA Weekly Review looks at the FDA’s actions related to drug approvals, IND approvals, designations and more. Here’s a look at what happened this week.

  July 22, 2022

   · 

  4 min read

   · 

  Mark Terry
• 

  Drug Development

  As Omicron Mutates, Researchers Compare Efficacy of Therapeutic Antibodies and Antivirals

  Researchers evaluate just how well therapeutic antibodies and antivirals work against Omicron, Vaxart’s oral vaccine shows early promise and hypertension doubles the risk of hospitalization.

  July 22, 2022

   · 

  6 min read

   · 

  Mark Terry
• 

  Business

  Chinese Biotechs Garner Millions for Shingles Vaccine Candidate to Rival GSK’s Shingrix

  Maxvax and Luzhu are raising funds to move their respective research and development programs for recombinant herpes zoster vaccine candidates and new adjuvant products.

  July 22, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  VistaGen’s Nasal Spray for Social Anxiety Disorder Falls Short in Phase III Trial

  VistaGenTherapeutics announced data showing that its nasal spray candidate for anxiety, depression and other central nervous system disorders, fell short of its primary endpoint.

  July 22, 2022

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Employer Resources

  Why and How Life Science Companies Should Prioritize Gender Inclusion

  Increasing gender inclusion in the life science industry is critical to its success. By making a commitment to diversity, companies can create an environment that will lead to long-term success.

  July 22, 2022

   · 

  3 min read

   · 

  Franklin Carpenter